Ravasio, R., Cranmer, H., Kearns , I., Viti, R. and Corinti, S. (2022) “Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor”, AboutOpen, 9(1), pp. 92–104. doi: 10.33393/ao.2022.2450.